A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (NCT04557059)
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.
Who can join: Review the eligibility criteria below.
Location: Arizona Urology Specialists — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (141 Sites)
Showing the first 25 of 141 sites.
- Arizona Urology Specialists — Tucson, Arizona
- Arkansas Urology — Little Rock, Arkansas
- Colorado Clinical Research — Lakewood, Colorado
- Urological Research Network — Hialeah, Florida
- First Urology, PSC — Jeffersonville, Indiana
- Michigan Institute of Urology — Troy, Michigan
- Associated Medical Professionals of Ny — Syracuse, New York
- The Urology Group — Cincinnati, Ohio
- Oregon Urology Institute — Springfield, Oregon
- MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Urology Austin — Austin, Texas
- Houston Metro Urology — Houston, Texas
- Spokane Urology — Spokane, Washington
- Bundaberg Hospital — Bundaberg,
- Hervey Bay Hospital — Bundaberg,
- Epworth Healthcare — East Melbourne,
- St Vincent's Hospital - Melbourne — Fitzroy,
- Genesis Care Hurstville — Hurstville,
- Macquarie University Hospital — North Ryde,
- Calvary Mater Newcastle — Waratah,
- GenesisCare Wembley — Wembley,
- Ordensklinikum Linz GmbH Elisabethinen — Linz,
- Universitaetsklinikum Salzburg Landeskrankenhaus — Salzburg,
- Medizinische Universitaet Wien — Vienna,
- ZAS Augustinus — Antwerp,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostatic Neoplasms
- A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer — Phoenix, Arizona
- PSMA PET/CT for Assessment of Recurrent Prostate Cancer — Vancouver, British Columbia
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS — Homewood, Alabama
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer — Los Angeles, California
- Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy — Fort-de-France,
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer — Birmingham, Alabama
Explore by condition: All Prostatic Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.